@article{a5c2be708b6d47c18a38e47018af4361,
title = "An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway",
author = "Deliang Guo and Felicia Reinitz and Mary Youssef and Cynthia Hong and David Nathanson and David Akhavan and Daisuke Kuga and Amzajerdi, {Ali Nael} and Horacio Soto and Shaojun Zhu and Ivan Babic and Kazuhiro Tanaka and Julie Dang and Akio Iwanami and Beatrice Gini and Jason DeJesus and Lisiero, {Dominique D.} and Huang, {Tiffany T.} and Prins, {Robert M.} and Wen, {Patrick Y.} and Robins, {H. Ian} and Prados, {Michael D.} and DeAngelis, {Lisa M.} and Mellinghoff, {Ingo K.} and Mehta, {Minesh P.} and James, {C. David} and Arnab Chakravarti and Cloughesy, {Timothy F.} and Peter Tontonoz and Mischel, {Paul S.}",
note = "Glioblastoma (GBM) is the most common malignant primary brain tumor of adults and one of the most lethal of all cancers. Epidermal growth factor receptor (EGFR) mutations (EGFRvIII) and phosphoinositide 3-kinase (PI3K) hyperactivation are common in GBM, promoting tumor growth and survival, including through sterol regulatory element-binding protein 1 (SREBP-1)-dependent lipogenesis.",
year = "2011",
month = oct,
day = "1",
doi = "10.1158/2159-8290.CD-11-0102",
language = "American English",
volume = "1",
journal = "Cancer Discovery",
}